We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now
Read MoreHide Full Article
Key Takeaways
QDEL posted strong Q1 2025 results, led by Labs and Molecular Diagnostics growth internationally.
QDEL expects Savanna and ARK Fentanyl II to drive recurring revenue and margin expansion.
QDEL faces risks from respiratory revenue decline and U.S. reimbursement policy dependence.
QuidelOrtho Corporation (QDEL - Free Report) is well-poised for growth in the coming quarters, courtesy of its strong product portfolio. The optimism, led by solid first-quarter 2025 results, is expected to contribute further. However, risks due to overdependence on the respiratory business and reimbursement policies persist.
This Zacks Rank #3 (Hold) company has lost 37.9% in the year-to-date period against 4.5% growth of the industry. The S&P 500 has witnessed 1.7% growth in the said time frame.
The renowned rapid diagnostic testing solutions provider has a market capitalization of $1.9 billion. QuidelOrtho’s earnings yield of 8.5% compares favorably with the industry’s 0.53%. The company’s earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 74.5%.
Image Source: Zacks Investment Research
Factors Favoring QDEL’s Growth
Robust Product Portfolio: QuidelOrtho continues to expand its diagnostic portfolio for both healthcare professionals and consumers, with key offerings like Sofia analyzers, QuickVue, and the innovative Savanna instrument, positioned to drive revenue and margin growth after a strong U.S. launch. With FDA approvals secured for the Savanna system and HSV panel, clinical trials for the respiratory and STI panels are slated for 2025. Further strengthening its Labs segment, the company added the ARK Fentanyl II Assay to its U.S. Vitros platforms in April 2024, addressing the rising demand for opioid testing and reinforcing its commitment to tackling evolving public health needs.
Potential in Diagnostic Business: QuidelOrtho’s focus on the diagnostics business has been a wise move, given the strong growth potential in this market. A Mordor Intelligence report states that the clinical diagnostics market is valued at approximately $84.2 billion in 2024 and is anticipated to reach $109.2 billion by 2029, at a CAGR of 5.5%. QuidelOrtho has used its expertise and know-how to develop differentiated diagnostic testing technologies and products that generate specialized results.
In each case, the company attempts to improve its performance in terms of ease of use, reduced cost, increased test accuracy and reduced time to result, thus attracting a growing range of customers and use cases.
Solid Q1 Results: QuidelOrtho delivered better-than-expected first-quarter 2025 results, driven by strong revenues from its Labs, Immunohematology, and Molecular Diagnostics segments in EMEA and other international markets. Margin expansion and solid bottom-line growth further underscored the company’s operational strength. Management highlighted continued momentum in its recurring revenue business model and reported steady progress on cost-savings initiatives, with additional measures planned to enhance efficiency and support margin improvement through 2025 and beyond, an encouraging outlook for the stock.
Factors That May Offset the Gains for QDEL
Third-Party Reimbursement Policies: QuidelOrtho's Point-of-Care products are primarily used by physicians and other healthcare providers. In the United States, these providers, including hospitals and physicians, typically depend on third-party payers, such as private health insurance, Medicare and Medicaid, to reimburse all or part of the cost of diagnostic procedures. The success of QuidelOrtho's products could be impacted if healthcare providers do not receive sufficient reimbursement from third-party payers for the costs associated with its products.
Overdependence on Respiratory Segment: A significant risk for QuidelOrtho is its continued dependence on the respiratory segment, which historically has accounted for a substantial portion of total revenues. In 2024, respiratory revenues totaled $503.9 million, accounting for approximately 18% of the company's total annual revenues of $2.78 billion.
While this represents a reduction from prior years, largely due to the expected normalization of COVID-19 testing demand, it underscores the pivotal role the respiratory portfolio—comprising COVID-19, influenza, RSV and strep tests—plays in the company’s overall financial health. Notably, respiratory revenues declined 29.5% year over year in 2024, caused by decreased COVID-19 testing volumes and a return to more typical, less volatile flu seasons.
Estimate Trend
QuidelOrtho is witnessing a positive estimate revision trend for 2025. In the past 60 days, the Zacks Consensus Estimate for its earnings has moved north by 5 cents to $2.39 per share.
The Zacks Consensus Estimate for the company’s second-quarter 2025 revenues is pegged at $611.3 million, indicating a 4% decline from the year-ago quarter’s reported number.
Key Picks
Some better-ranked stocks in the broader medical space that have announced quarterly results are CVS Health Corporation (CVS - Free Report) , Integer Holdings Corporation (ITGR - Free Report) and AngioDynamics (ANGO - Free Report) .
Revenues of $94.59 billion outpaced the consensus mark by 1.8%. CVS Health has a long-term estimated growth rate of 11.4%. Its earnings surpassed estimates in each of the trailing four quarters, with an average surprise of 18.1%.
Integer Holdings reported first-quarter 2025 adjusted EPS of $1.31, beating the Zacks Consensus Estimate by 3.2%. Revenues of $437.4 million surpassed the Zacks Consensus Estimate by 1.3%. It currently sports a Zacks Rank #1.
Integer Holdings has a long-term estimated growth rate of 18.4%. ITGR’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 2.8%.
AngioDynamics, currently sporting a Zacks Rank #1, reported a third-quarter fiscal 2025 adjusted EPS of 3 cents against the Zacks Consensus Estimate of a 13-cent loss. Revenues of $72 million beat the Zacks Consensus Estimate by 2%.
ANGO has an estimated fiscal 2026 earnings growth rate of 27.8% compared with the S&P 500 Composite’s 10.5% growth. AngioDynamics’ earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 70.9%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now
Key Takeaways
QuidelOrtho Corporation (QDEL - Free Report) is well-poised for growth in the coming quarters, courtesy of its strong product portfolio. The optimism, led by solid first-quarter 2025 results, is expected to contribute further. However, risks due to overdependence on the respiratory business and reimbursement policies persist.
This Zacks Rank #3 (Hold) company has lost 37.9% in the year-to-date period against 4.5% growth of the industry. The S&P 500 has witnessed 1.7% growth in the said time frame.
The renowned rapid diagnostic testing solutions provider has a market capitalization of $1.9 billion. QuidelOrtho’s earnings yield of 8.5% compares favorably with the industry’s 0.53%. The company’s earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 74.5%.
Image Source: Zacks Investment Research
Factors Favoring QDEL’s Growth
Robust Product Portfolio: QuidelOrtho continues to expand its diagnostic portfolio for both healthcare professionals and consumers, with key offerings like Sofia analyzers, QuickVue, and the innovative Savanna instrument, positioned to drive revenue and margin growth after a strong U.S. launch. With FDA approvals secured for the Savanna system and HSV panel, clinical trials for the respiratory and STI panels are slated for 2025. Further strengthening its Labs segment, the company added the ARK Fentanyl II Assay to its U.S. Vitros platforms in April 2024, addressing the rising demand for opioid testing and reinforcing its commitment to tackling evolving public health needs.
Potential in Diagnostic Business: QuidelOrtho’s focus on the diagnostics business has been a wise move, given the strong growth potential in this market. A Mordor Intelligence report states that the clinical diagnostics market is valued at approximately $84.2 billion in 2024 and is anticipated to reach $109.2 billion by 2029, at a CAGR of 5.5%. QuidelOrtho has used its expertise and know-how to develop differentiated diagnostic testing technologies and products that generate specialized results.
In each case, the company attempts to improve its performance in terms of ease of use, reduced cost, increased test accuracy and reduced time to result, thus attracting a growing range of customers and use cases.
Solid Q1 Results: QuidelOrtho delivered better-than-expected first-quarter 2025 results, driven by strong revenues from its Labs, Immunohematology, and Molecular Diagnostics segments in EMEA and other international markets. Margin expansion and solid bottom-line growth further underscored the company’s operational strength. Management highlighted continued momentum in its recurring revenue business model and reported steady progress on cost-savings initiatives, with additional measures planned to enhance efficiency and support margin improvement through 2025 and beyond, an encouraging outlook for the stock.
Factors That May Offset the Gains for QDEL
Third-Party Reimbursement Policies: QuidelOrtho's Point-of-Care products are primarily used by physicians and other healthcare providers. In the United States, these providers, including hospitals and physicians, typically depend on third-party payers, such as private health insurance, Medicare and Medicaid, to reimburse all or part of the cost of diagnostic procedures. The success of QuidelOrtho's products could be impacted if healthcare providers do not receive sufficient reimbursement from third-party payers for the costs associated with its products.
Overdependence on Respiratory Segment: A significant risk for QuidelOrtho is its continued dependence on the respiratory segment, which historically has accounted for a substantial portion of total revenues. In 2024, respiratory revenues totaled $503.9 million, accounting for approximately 18% of the company's total annual revenues of $2.78 billion.
While this represents a reduction from prior years, largely due to the expected normalization of COVID-19 testing demand, it underscores the pivotal role the respiratory portfolio—comprising COVID-19, influenza, RSV and strep tests—plays in the company’s overall financial health. Notably, respiratory revenues declined 29.5% year over year in 2024, caused by decreased COVID-19 testing volumes and a return to more typical, less volatile flu seasons.
Estimate Trend
QuidelOrtho is witnessing a positive estimate revision trend for 2025. In the past 60 days, the Zacks Consensus Estimate for its earnings has moved north by 5 cents to $2.39 per share.
The Zacks Consensus Estimate for the company’s second-quarter 2025 revenues is pegged at $611.3 million, indicating a 4% decline from the year-ago quarter’s reported number.
Key Picks
Some better-ranked stocks in the broader medical space that have announced quarterly results are CVS Health Corporation (CVS - Free Report) , Integer Holdings Corporation (ITGR - Free Report) and AngioDynamics (ANGO - Free Report) .
CVS Health, carrying a Zacks Rank of 2 (Buy), reported first-quarter 2025 adjusted earnings per share (EPS) of $2.25, beating the Zacks Consensus Estimate by 31.6%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Revenues of $94.59 billion outpaced the consensus mark by 1.8%. CVS Health has a long-term estimated growth rate of 11.4%. Its earnings surpassed estimates in each of the trailing four quarters, with an average surprise of 18.1%.
Integer Holdings reported first-quarter 2025 adjusted EPS of $1.31, beating the Zacks Consensus Estimate by 3.2%. Revenues of $437.4 million surpassed the Zacks Consensus Estimate by 1.3%. It currently sports a Zacks Rank #1.
Integer Holdings has a long-term estimated growth rate of 18.4%. ITGR’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 2.8%.
AngioDynamics, currently sporting a Zacks Rank #1, reported a third-quarter fiscal 2025 adjusted EPS of 3 cents against the Zacks Consensus Estimate of a 13-cent loss. Revenues of $72 million beat the Zacks Consensus Estimate by 2%.
ANGO has an estimated fiscal 2026 earnings growth rate of 27.8% compared with the S&P 500 Composite’s 10.5% growth. AngioDynamics’ earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 70.9%.